Clinical Trial Update: Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N [Phase 3]

View source ↗

Summary

Open-label Phase 3 switch study evaluating the virological efficacy of a dolutegravir/rilpivirine fixed-dose combination in ART-experienced, virologically suppr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Edurant (rilpivirine)
• Juluca (dolutegravir + rilpivirine)
• Tivicay (dolutegravir)

Snippet

Sponsor: NEAT ID Foundation | Conditions: HIV-1-infection | Phase 3 | Status: COMPLETED | Results posted: 2024-12-24